Want to join the conversation?
Drug retailing chain $WBA said that 1Q16 net sales were $29Bil, an increase of 48.5% vs. 1Q15 and adjusted net diluted EPS was $1.03, an increase of 32.1% vs. 1Q15. The increase in performance was primarily due to the Alliance Boots transaction and growth in the Retail Pharmacy USA segment.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.